| Gene Symbol | CERS2 |
| Full Name | Ceramide Synthase 2 (Lass2) |
| Aliases | Ceramide Synthase 2, also known as Lass2 |
| Chromosome | 1q42.2 |
| Protein Type | Enzyme |
| Target Class | Enzyme |
| Function | CERS2 inhibitors would reduce the enzymatic synthesis of very long-chain ceramides by blocking the condensation of serine and palmitoyl-CoA, thereby decreasing ceramide-mediated neuroinflammation a... |
| Mechanism of Action | CERS2 inhibitors would reduce the enzymatic synthesis of very long-chain ceramides by blocking the condensation of serine and palmitoyl-CoA, thereby decreasing ceramide-mediated neuroinflammation and apoptosis implicated in neurodegenerative pathology. This modulation of the ceramide signaling cascade may provide neuroprotective effects in Alzheimer's disease and related neurodegenerative conditions. |
| Druggability | Low (0.28) |
| Clinical Stage | Phase II |
| Molecular Weight | 44 kDa |
| Amino Acids | 380 aa |
| Pathways | Effect |
| UniProt ID | H0YNU7 |
| NCBI Gene ID | 29956 |
| Ensembl ID | ENSG00000156599 |
| OMIM | 606922 |
| GeneCards | CERS2 |
| Human Protein Atlas | CERS2 |
| Associated Diseases | AD, AMI, ARDS, ARM, Aging, ILD |
| Known Drugs/Compounds | fingolimod |
| Interactions | SGMS1, SGMS2, CERS6, IR, BCL-2, AND |
| SciDEX Target | View Target Profile (2 clinical trials) |
| SciDEX Hypotheses | Sphingolipid Metabolism Reprogramming |
| KG Connections | 213 knowledge graph edges |
| Databases | GeneCardsHPASTRING |